BiondVax universal flu vaccine shows positive independent results

BiondVax universal flu vaccine shows positive independent results.
BiondVax universal flu vaccine shows positive independent results. | Courtesy of

BiondVax Pharmaceuticals Ltd. recently announced that the independent results of its universal flu vaccine (M-001) show effective immunogenicity against H3N2.

The BVX-005 phase II trial, which was held in 2012, was studied under statistical analysis. The analysis shows that the trial’s participants showed an improved immunogenicity against flu strains that were not present when the study was conducted. The most well-known new strain is the H3N2 influenza strain, which cause the U.S. epidemic in 2015.

The trial included 120 elderly participants who were 65 or more years old. When the trial ended, it was considered to be successful because the patients showed positive immune responses on both cellular and humoral levels. The vaccine protected the participants against several influenza viruses.

"We are happy that the participants which received our vaccine in the trial three years ago present a higher immunogenicity, even to actual flu strains in circulation now,” Ron Babecoff, BiondVax's president and CEO, said. “The independently provided statistical analysis we reported today is very important as it demonstrates that M-001 provides a safety net by broadening the immunogenicity to existing and future flu strains -- in this case, against a specific flu strain that back when the trial was conducted, did not yet exist. If our vaccine was approved by the necessary regulatory bodies and available in the market during the last winter, we believe that the recent epidemic could have been prevented. These results are another important data point showing the importance of our work for global public health and in particular for the elderly which are most vulnerable to this dangerous virus."

Organizations in this Story


Want to get notified whenever we write about BiondVax ?
Next time we write about BiondVax, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.